Publications

CD200Fc:

1) Rygiel et al. 2009. Lack of CD200 enhances pathological T cell responses during influenza infection. J. Immunol. 183:1990.

2) Sarangi et al. 2009. Control of viral immunoinflammatory lesions by manipulating CD200:CD200 receptor interaction. Clin. Immunol. 131:31.

3) Wissinger et al. 2009. Immune homeostasis in the respiratory tract and its impact on heterologous infection. Semin. Immunol. 21:147.

4) Snelgrove et al. 2008. A critical function for CD200 in lung immune homeostasis and severity of influenza infection. Nat. Immunol. 9:1074.

5) Simelyte et al. 2008. CD200-Fc, a novel antiarthritic biologic agent that targets proinflammatory cytokine expression in the joints of mice with collagen-induced arthritis. Arthritis Rheum. 58:1038.

6) Meuth et al. 2008. CNS inflammation and neuronal degeneration is aggravated by impaired CD200-CD200R-mediated macrophage silencing. J. Neuroimmunol. 194:62.

CD200mAb:

1) Kawasaki et al. 2008. Cancer stem cells, CD200 and immunoevasion. Trends Immunol. 29:464.

2) Kretz-Rommel et al. 2008. Blockade of CD200 in the presence or absence of antibody effector function: implications for anti-CD200 therapy. J. Immunol. 180:699.

3) Moreaux et al. 2008. CD200: a putative therapeutic target in cancer. Biochem. Biophys. Res. Commun. 366:117.

4) Siva et al. 2008. Immune modulation by melanoma and ovarian tumor cells through expression of the immunosuppressive molecule CD200. Cancer Immunol. Immunother. 57:987.

5) Petermann et al. 2007. CD200 is induced by ERK and is a potential therapeutic target in melanoma. J. Clin. Invest. 117:3922.

6) Tonks et al. 2007. CD200 as a prognostic factor in acute myeloid leukemia. Leukemia 12:566.

CD47Fc:

1) Matozaki et al. 2009. Function and molecular mechanisms of the CD47-SIRPalpha signaling pathway. Trends Cell Biol. 19:72.

2) Barclay 2009. Signal regulatory protein alpha (SIRPa)/CD47 interaction and function. Curr. Opin. Immunol. 21:1.

3) Van den Berg et al. 2008. Innate immune 'self' recognition: a role for CD47-SIRPalpha interactions in hematopoietic stem cell transplantation. Trends Immunol. 29:203.

4) Tsai et al. 2008. Inhibition of 'self' engulgment through deactivation of myosin-II at the phagocytic synapse between human cells. J Cell Biol. 180-989.

5) Takenaka et al. 2007. Polymorphism in SIRPalpha modulates engraftment of human hematopoietic stem cells. Nat Immunol. 8:1313.

SIRPaFc:

1) Richie and Smyth 2009. A new therapeutic target for leukemia comes to the surface. Cell 138:226.

2) Jaiswai et al. 2009. CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis. Cell 138:271.

3) Majeti et al. 2009. CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells. Cell 138:286.

4) Chan et al. 2009. Identification, molecular characterization, clinical prognosis, and therapeutic targeting of human bladder tumor-initiating cells. Proc. Natl. Acad. Sci. 106:14016.

FcgRIIa RIIa (TTI-314 mAb):

1) Pietersz et al. 2009. Inhibition of destructive autoimmune arthritis in FcgammaRIIa transgenic mice by small chemical entities. Immunol. Cell Biol. 87:3.

2) Tsuboi et al. 2008. Human neutrophil Fcgamma receptors initiate and play specialized nonredundant roles in antibody-mediated inflammatory diseases. Immunity 28:833.

3) Belostocki et al. 2008. Infliximab treatment shifts the balance between stimulatory and inhibitory Fcgamma receptor type II isoforms on neutrophils in patients with rheumatoid arthritis. Arthritis Rheum. 58:384.

4) Clavel et al. 2008. Induction of macrophage secretion of tumor necrosis factor alpha through Fcgamma receptor IIa engagement by rheumatoid arthritis-specific autoantibodies to citrullinated proteins complexed with fibrinogen. Arthritis Rheum. 58:678.

5) Mullazehi et al. 2006. Surface-bound anti-type II collagen-containing immune complexes induce production of tumor necrosis factor alpha, interleukin-1beta, and interleukin-8 from peripheral blood monocytes via Fc gamma receptor IIA: a potential pathophysiologic mechanism for humoral anti-type II collagen immunity in arthritis. Arthritis Rheum. 54:1759.

6) Mathsson et al. 2006. Immune complexes from rheumatoid arthritis synovial fluid induce FcgammaRIIa dependent and rheumatoid factor correlated production of tumour necrosis factor-alpha by peripheral blood mononuclear cells. Arthritis Res. Ther. 8:R64.

TTI-1612 (IC indication):

1) Hanno et al. 2009. Status of international consensus on interstitial cystitis/bladder pain syndrome/painful bladder syndrome: 2008 snapshot. Neurourol Urodyn. 28:274.

2) Kim et al. 2009. Heparin-binding epidermal growth factor-like growth factor functionally antagonizes interstitial cystitis antiproliferative factor via mitogen-activated protein kinase pathway activation. BJU Int. 103:541.

3) Sun et al. 2007. EGF and HB-EGF modulate inward potassium current in human bladder urothelial cells from normal and interstitial cystitis patients. Am. J. Physiol. Cell Physiol. 292:C106.

TTI-1612 (NEC indication):

1) Henry and Moss 2009. Necrotizing enterocolitis. Ann. Rev. Med. 60:111.

2) Radulescu et al. 2009. Preclinical neonatal rat studies of heparin-binding EGF-like growth factor in protection of the intestines from necrotizing enterocolitis. Pediatr. Res. 65:437.

3) Yu et al. 2009. Heparin-binding EGF-like growth factor increases intestinal microvascular blood flow in necrotizing enterocolitis. Gastroenterology 137:221.

4) Zhang et al. 2009. Heparin-binding epidermal growth factor-like growth factor is essential for preservation of gut barrier function after hemorrhagic shock and resuscitation in mice. Surgery 146:334.

5) Feng et al. 2007. Heparin-binding epidermal growth factor-like growth factor promotes enterocyte migration and proliferation in neonatal rats with necrotizing enterocolitis. J. Pediatr. Surg. 42:214.